Cooper Co (COO) Investors: BMO Capital Reiterates “Buy” Rating, Sees $272.0/Share; Genmark Diagnostics (GNMK) Has 4 Sentiment

November 15, 2017 - By Louis Casey

GenMark Diagnostics, Inc. is a molecular diagnostics company. The company has market cap of $258.08 million. The Firm is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It currently has negative earnings. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Among 15 analysts covering Cooper (NYSE:COO), 10 have Buy rating, 0 Sell and 5 Hold. Therefore 67% are positive. Cooper has $280.0 highest and $136 lowest target. $226.80’s average target is -4.21% below currents $236.78 stock price. Cooper had 50 analyst reports since August 26, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Friday, September 4 report. As per Monday, August 28, the company rating was maintained by KeyBanc Capital Markets. The stock of Cooper Companies Inc (NYSE:COO) earned “Buy” rating by Stifel Nicolaus on Friday, September 1. Robert W. Baird maintained Cooper Companies Inc (NYSE:COO) rating on Monday, October 16. Robert W. Baird has “Buy” rating and $273.0 target. The firm has “Buy” rating given on Tuesday, July 25 by BMO Capital Markets. On Monday, August 31 the stock rating was downgraded by Zacks to “Hold”. The firm has “Outperform” rating given on Friday, September 4 by BMO Capital Markets. Stifel Nicolaus maintained it with “Buy” rating and $195 target in Thursday, June 30 report. Jefferies maintained it with “Buy” rating and $250.0 target in Thursday, August 17 report. Jefferies maintained Cooper Companies Inc (NYSE:COO) on Tuesday, May 30 with “Buy” rating.

Analysts await Cooper Companies Inc (NYSE:COO) to report earnings on December, 7 after the close. They expect $2.65 earnings per share, up 16.23% or $0.37 from last year’s $2.28 per share. COO’s profit will be $129.71 million for 22.34 P/E if the $2.65 EPS becomes a reality. After $2.64 actual earnings per share reported by Cooper Companies Inc for the previous quarter, Wall Street now forecasts 0.38% EPS growth.

The stock decreased 0.15% or $0.35 during the last trading session, reaching $236.78. About shares traded. Cooper Companies Inc (NYSE:COO) has risen 33.48% since November 15, 2016 and is uptrending. It has outperformed by 16.78% the S&P500.

Since June 6, 2017, it had 0 insider purchases, and 3 selling transactions for $12.21 million activity. KAUFMAN CAROL R also sold $10.71 million worth of Cooper Companies Inc (NYSE:COO) on Wednesday, June 7. Another trade for 816 shares valued at $198,400 was made by ZINBERG STANLEY MD on Tuesday, June 6.

The Cooper Companies, Inc. is a global medical device company. The company has market cap of $11.59 billion. The Firm operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. It has a 33.98 P/E ratio. CooperVision offers soft contact lenses for the vision correction market.

Investors sentiment increased to 1.35 in Q2 2017. Its up 0.09, from 1.26 in 2017Q1. It improved, as 20 investors sold Cooper Companies Inc shares while 135 reduced holdings. 69 funds opened positions while 141 raised stakes. 46.02 million shares or 0.41% less from 46.21 million shares in 2017Q1 were reported. Mai Capital invested in 5,882 shares. Legacy Private accumulated 915 shares. Gareth Morgan Invs Ltd Partnership invested in 4,900 shares or 0.11% of the stock. Cramer Rosenthal Mcglynn Ltd Liability holds 101,762 shares or 0.37% of its portfolio. Norinchukin Bank & Trust The has 0.02% invested in Cooper Companies Inc (NYSE:COO) for 3,390 shares. Arrowmark Colorado Limited Liability Corp reported 237,117 shares or 0.7% of all its holdings. Ameriprise Fin has 0.03% invested in Cooper Companies Inc (NYSE:COO). Pictet Savings Bank And reported 0.43% stake. Livforsakringsbolaget Skandia Omsesidigt reported 900 shares or 0.02% of all its holdings. Commonwealth Equity Svcs invested 0.01% in Cooper Companies Inc (NYSE:COO). Clinton Group Incorporated accumulated 5,846 shares or 0.14% of the stock. The Missouri-based Stifel Fin Corp has invested 0.01% in Cooper Companies Inc (NYSE:COO). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Corporation reported 13,300 shares. Arrowstreet Cap Partnership accumulated 0.04% or 57,900 shares. Moreover, Prelude Mgmt has 0.05% invested in Cooper Companies Inc (NYSE:COO).

Cadian Capital Management Lp holds 2.3% of its portfolio in GenMark Diagnostics, Inc for 3.99 million shares. Ghost Tree Capital Llc owns 825,000 shares or 2.03% of their US portfolio. Moreover, Northpointe Capital Llc has 1.55% invested in the company for 1.25 million shares. The Illinois-based Hightower Advisors Llc has invested 0.24% in the stock. Needham Investment Management Llc, a New York-based fund reported 50,000 shares.

The stock decreased 0.63% or $0.03 during the last trading session, reaching $4.71. About shares traded. GenMark Diagnostics, Inc (GNMK) has risen 116.11% since November 15, 2016 and is uptrending. It has outperformed by 99.41% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 4 selling transactions for $14,591 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com